MAPT and Alzheimer disease: In the Amyloid Tau Neurodegeneration (ATN) framework, amyloid positive in PiB-PET and low levels of CSF amyloid-β1–42 are amyloid markers, and AD findings of FDG-PET and hippocampal atrophy in MRI as well as high levels of CSF total tau are neurodegeneration markers.